Home › Huntington's Disease › NCT06546488
Cognitive Assessment Tools for Huntington's Disease.
Cognitive Assessment Tools for Individuals With Huntington's Disease.
Who can join
Ages 30 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form. 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40. 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4. 4. Vision and hearing sufficient for compliance with tests. 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form. Exclusion Criteria: 1. Age of symptom onset less than 19 years old or greater than 60 years old. 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant. 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure). 4. Subjects who are pregnant or breast feeding 5. Subjects with a history of a learning disability. 6. Subjects who are unable to provide consent.
About the study
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
What is being tested
- Assessments (behavioral)
Sponsor: Ohio State University · Participants: 76 · Started: Jun 20, 2025
Contact the study team
- Nicole E Vrettos · Phone: 6143668642
Official record on ClinicalTrials.gov — NCT06546488
Locations in the U.S.
| Ohio | The Ohio State University Wexner Medical Center, Columbus |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.